Jul 08, 2026
By Transpire Insight
Description
According to a research report published by Transpire Insight, The Global Exosomes Market Size is projected to Grow from USD 0.95 Billion in 2026 to USD 7.12 Billion by 2035, at a CAGR of 35.00% during the forecast period 2026-2035. The Exosomes Market is experiencing rapid growth owing to increased investments in the field of regenerative medicine, increased research in extracellular vesicles, and growing demand for drug delivery systems as well as diagnostics technologies. The increasing incidences of cancers, neurological disorders, cardiovascular diseases, and chronic inflammatory disorders have been propelling the use of exosome-based therapeutic products and biomarker discovery tools. In addition, the development of technology for exosome isolation, purification, analysis, and manufacturing along with increased collaboration among biotech companies, pharmaceutical companies, and academic institutes is likely to support market growth during the forecast period.
Introduction
The Exosomes Market concentrates on innovations in the creation, manufacturing, and commercialization of exosome-derived products used in various therapeutic, diagnostic, and research applications. Exosomes are small extracellular vesicles produced naturally by cells for intercellular communication via the transfer of protein, lipids, RNA, and other biological active components. The specific biological nature of these vesicles enables their use in targeted drug delivery, regenerative medicine, liquid biopsy, biomarker identification, oncology, neurodegenerative diseases, cardiovascular diseases, and cosmetics. Developments in cell and gene therapies and extracellular vesicle research are driving the increasing use of exosomes in the biotechnology and pharmaceutical industry.
Recent Development News,
June 2026: Announced the continuing progress in developing its exosome platform, conducting further studies of exosome therapy and drug delivery systems targeting regenerative medicine uses.
May 2026: Rapid progress towards the development of its EV/exosome pipeline of therapies for inflammatory and dermatological indications, through ongoing clinical development efforts.
Stay Ahead of Emerging Opportunities with Expert Market Insights by Transpire Insight
The results presented through the medium of this blog have been obtained through extensive market research conducted by Transpire Insight, which is a trustworthy advisory firm for many of the leading companies around the world. The reports that we offer are the results of extensive analysis and projections along with specific industry details that enable decision-makers to identify possible areas where there may be scope for development in the fast-evolving industries. The customers who need market segmentation, competitor analysis, regional point of view and projections regarding future investments would greatly gain from the comprehensive report.
Download the exclusive Exosomes Market sample report today to uncover expert insights, emerging trends, and the opportunities defining the future of the industry.
Exosomes MarketSize & Statistics
Market Size of the Exosomes Market was projected to be USD 0.95 billion in 2026.
The Market is Expected to Grow at a CAGR of 35.00% from 2026 to 2035.
The Market Size of the Global Exosomes Market Size is expected to be USD 7.12 billion in 2035.
The demand from North America is expected to be the highest during the forecast period, contributing to about 47.7% of the overall market share for the Exosomes Market. The reasons for this include high biotechnological research, pharmaceutical and biopharmaceutical industries, investment in regenerative medicines, fundings for research, and leading exosome technologies companies.
The growth rate of the Asia-Pacific region will be the highest during the forecast period, reaching a CAGR of about 35.4%. Growth is due to growing infrastructure of biotechnology, investment in cell and gene therapy research, increase in the number of clinical trials, healthcare spending, and support from governments of different countries including China, Japan, South Korea, and India.
Regional Growth and Demand Analysis by Transpire Insight:
North America is the largest region in the Exosomes Market, with an estimated 43.3% share of the global market. Factors attributing to the dominance of North America include well-developed biotech and pharma industry, high investments in regenerative medicine, and focus on precision medicine and novel therapies. The presence of major players in the field of biotechnology, along with research and academic institutes actively involved in exosome studies, has facilitated rapid innovations in exosome-based diagnosis and therapy. In addition, government grants, positive regulatory scenarios for conducting clinical studies, rise in use of liquid biopsy techniques, and increase in the number of clinical trials are contributing to the dominance of North America in the global exosomes market.
Asia-Pacific is projected to be the fastest-growing region over the forecast period, owing to development in biotech infrastructure, increased investments in life sciences research, and increasing demand for innovative solutions in regenerative medicine. Countries like China, Japan, South Korea, and India have increased their funding in cell therapy, extracellular vesicles studies, and precision medicine. Increased healthcare spending, supportive government policies, and increased clinical study activity are some of the key factors expected to propel the growth of exosome technologies in the region.
Top 15 Trends in the Exosomes Market
Growing Adoption of Exosome-Based Drug Delivery Systems
Increasing Development of Exosome-Based Regenerative Therapies
Rising Use of Exosomes in Liquid Biopsy and Cancer Diagnostics
Expansion of Stem Cell-Derived Exosome Research
Growing Investments in Extracellular Vesicle Manufacturing Technologies
Increasing Adoption of AI-Driven Exosome Biomarker Discovery
Development of GMP-Grade Exosome Production Platforms
Growing Application of Exosomes in Neurological Disease Treatment
Expansion of Exosome-Based Cosmetic and Skin Regeneration Products
Increasing Clinical Trials for Exosome Therapeutics
Advancements in Exosome Isolation and Purification Technologies
Growing Strategic Partnerships Between Biotechnology and Pharmaceutical Companies
Expansion of Personalized Medicine Through Exosome Technologies
Increasing Regulatory Focus on Exosome Quality and Standardization
Growing Use of Engineered Exosomes for Targeted Gene and RNA Delivery
Proceed to Checkout to purchase the exclusive Exosomes Market report and gain instant access to in-depth market intelligence, strategic analysis, and future growth opportunities.
1. Growing Adoption of Exosome-Based Drug Delivery Systems
Exosome-based drug delivery is emerging as one of the most promising trends in the exosomes market due to the natural ability of exosomes to transport therapeutic molecules directly to target cells. Researchers are increasingly developing engineered exosomes capable of delivering drugs, proteins, RNA, and gene therapies with high precision while minimizing side effects. This technology has significant potential for treating cancer, neurological disorders, and inflammatory diseases, making it a major focus of pharmaceutical innovation.
2. Increasing Development of Exosome-Based Regenerative Therapies
Regenerative medicine is increasingly utilizing exosomes as a cell-free therapeutic alternative for tissue repair and healing. Exosomes derived from stem cells contain bioactive molecules that promote cell regeneration, reduce inflammation, and accelerate tissue recovery without many of the safety concerns associated with stem cell transplantation. Growing research in wound healing, orthopedic disorders, cardiovascular diseases, and neurological regeneration is driving the expansion of exosome-based regenerative therapies.
3. Rising Use of Exosomes in Liquid Biopsy and Cancer Diagnostics
Exosomes are gaining widespread attention in liquid biopsy applications because they carry molecular biomarkers such as proteins, DNA, RNA, and microRNA that reflect the condition of their originating cells. Their presence in blood, urine, saliva, and other body fluids enables non-invasive detection and monitoring of cancer and other diseases. Advances in exosome-based diagnostic technologies are improving early disease detection, treatment monitoring, and personalized medicine strategies.
4. Expansion of Stem Cell-Derived Exosome Research
Stem cell-derived exosomes are becoming a major area of scientific research due to their therapeutic potential across multiple disease areas. Researchers are investigating their ability to support tissue regeneration, immune modulation, and cell communication while avoiding many challenges associated with live cell therapies. Increasing academic collaborations, clinical studies, and biotechnology investments are accelerating the development of standardized stem cell-derived exosome products.
5. Growing Investments in Extracellular Vesicle Manufacturing Technologies
As demand for exosome-based therapeutics grows, companies are investing heavily in advanced manufacturing technologies that improve exosome isolation, purification, scalability, and quality control. Automated production platforms, high-throughput purification systems, and Good Manufacturing Practice (GMP)-compliant facilities are helping manufacturers produce clinical-grade exosomes suitable for commercial applications. These technological advancements are supporting the transition of exosome therapies from research laboratories to large-scale clinical use.
6. Increasing Adoption of AI-Driven Exosome Biomarker Discovery
Artificial intelligence and machine learning are transforming exosome research by accelerating the identification of disease-specific biomarkers and improving data analysis. AI-powered platforms can analyze complex exosomal molecular profiles to discover new diagnostic and therapeutic targets more efficiently than traditional methods. This trend is enhancing precision medicine, enabling earlier disease diagnosis, and supporting the development of personalized treatment strategies based on exosome-derived biomarkers.
Top 25 Companies Leading the Exosomes Market
Thermo Fisher Scientific Inc.
Lonza Group AG
Bio-Techne Corporation
QIAGEN N.V.
SBI (System Biosciences LLC)
Aegle Therapeutics Corporation
Capricor Therapeutics, Inc.
Evox Therapeutics Ltd.
RoosterBio, Inc.
Codiak BioSciences, Inc.
Exopharm Limited
Creative Biolabs
Anjarium Biosciences AG
Aruna Bio, Inc.
Kimera Labs
NX Pharmagen
Exocel Bio
Exosome Diagnostics
Miltenyi Biotec
NanoSomiX, Inc.
Unchained Labs
Particle Metrix GmbH
HansaBioMed Life Sciences Ltd.
Norgen Biotek Corp.
Izon Science Ltd.
Customize the exclusive Exosomes Market report today to receive tailored insights, country-specific analysis, and business-focused market intelligence.
1. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is an international life sciences organization located in Waltham.
It offers laboratory equipment, instrumentation, and biotechnology products, including exosome isolation and characterization solutions.
Founded: 2006 | Headquarters: Waltham, Massachusetts, USA
Why It Ranks:
Thermo Fisher Scientific is one of the key suppliers of exosome research solutions, innovative analytical technologies, and life science products used in the biotech and pharmaceutical research.
Regional Dominance:
North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
Product Line:
Exosome isolation kits, analytical instruments, flow cytometry systems, sequencing solutions, cell culture products, and molecular biology reagents.
Recent Development:
In 2025, Thermo Fisher Scientific expanded its extracellular vesicles research solutions with new analytical workflows and sample preparation technologies.
2. Lonza Group AG
Lonza Group AG is an international company operating in the life sciences industry. The company offers services such as contract development and manufacturing, cell and gene therapies, and exosomes manufacturing solutions.
Founded: 1897 | Headquarters: Basel, Switzerland
Why It Ranks:
Lonza is a highly ranking company because of its skills in GMP manufacture, bioprocesses, and large-scale production of exosomes.
Regional Dominance:
Europe, North America, Asia-Pacific, and Latin America.
Product Line:
Services in the manufacture of exosomes, solutions for cells therapy, bioprocessing, GMP manufacturing, and analytical services.
Recent Development:
In 2026, Lonza enhanced its exosomes development and manufacturing services.
3. Bio-Techne Corporation
Bio-Techne Corporation is a biotechnology firm based in Minneapolis.
Bio-Techne develops reagents, diagnostic tests, and solutions for exosomes research for biotechnology and pharmaceuticals industries.
Founded: 1976 | Headquarters: Minneapolis, Minnesota, USA
Why It Ranks:
Bio-Techne is distinguished by its technology for exosome isolation, characterization, and biomarker research.
Regional Dominance:
North America, Europe, and Asia Pacific.
Product Line:
Exosome isolation kits, antibodies, proteins, molecular diagnostics, biomarker assays, and laboratory reagents.
Recent Development:
In 2025, Bio-Techne introduced new exosome analysis products line for extracellular vesicles research.
4. QIAGEN N.V.
QIAGEN N.V. is a molecular diagnostics and life sciences business located in Venlo. The company specializes in developing technologies such as sample preparation, molecular detection, and biomarker discovery, which includes exosomes isolation technology.
Founded: 1984 | Headquarters: Venlo, Netherlands
Why It Ranks:
QIAGEN is one of the main providers of exosome isolation technologies for precision medicine and liquid biopsies studies.
Regional Dominance:
Europe, North America, Asia Pacific, and Latin America.
Product Line:
Exosome isolation kits, nucleic acid purification technologies, PCR technologies, sequencing technologies, and liquid biopsy technologies.
Recent Development:
QIAGEN launched an advanced exosome isolation technology in 2025.
5. SBI (System Biosciences LLC)
SBI (System Biosciences LLC) is a biotech company based out of Palo Alto.
Areas of expertise: extracellular vesicle research products and exosome technology.
Founded: 2009 | Headquarters: Palo Alto, California, USA
Why It Ranks:
SBI is known for the range of its exosome isolation, purification, and characterization products that are utilized by research organizations globally.
Regional Dominance:
North America, Europe, and Asia-Pacific.
Product Line:
Isolation kits, purification equipment, RNA extraction kits, tools for extracellular vesicles, and molecular biology reagents.
Recent Development:
In 2025, SBI launched new exosome purification and RNA analysis tools.
6. Aegle Therapeutics Corporation
The Aegle Therapeutics Corporation is a biotechnology firm that is located in Miami.
Founded: 2015 | Headquarters: Miami, Florida, USA
Why It Ranks:
The Aegle Therapeutics Corporation is among the leading exosome therapeutic companies and it emphasizes the use of such therapies in regenerative medicine.
Regional Dominance:
North America and increasing international collaboration.
Product Line:
Exosomes, regenerative medicine products, extracellular vesicles, and inflammatory diseases therapies.
Recent Development:
In 2026, the company fast-tracked the development of exosome therapeutic drugs for dermatological and inflammatory diseases.
7. Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is an American biotechnology firm based in San Diego.
Founded: 2005 | Headquarters: San Diego, California, USA
Why It Ranks:
It is known for its unique StealthX™ exosome technology and cutting-edge pipeline of regenerative medicines.
Regional Dominance:
North America and the international market of clinical research.
Product Line:
Exosome-based therapies, regenerative medicines, drug delivery platforms, and cardiovascular treatments.
Recent Development:
In 2026, Capricor improved its engineered exosome technology to deliver targeted therapy.
8. Evox Therapeutics Ltd.
Evox Therapeutics Ltd. is an organization in the biotechnology sector based in Oxford.
Founded: 2016 | Headquarters: Oxford, England, United Kingdom
Why It Ranks:
Evox Therapeutics is at the forefront of engineered exosome drug delivery technology in rare diseases and precision medicines.
Regional Dominance:
European, North American and worldwide biotechnology markets.
Product Line:
Engineered exosome therapy, RNA delivery systems, protein therapy and drug delivery technology.
Recent Development:
In 2025, Evox Therapeutics extended its collaborations to hasten engineered exosome therapy for rare diseases.
9. RoosterBio, Inc.
RoosterBio, Inc. is a biotechnology firm based in Frederick. RoosterBio produces cell and exosome manufacturing technologies for regenerative medicine and advanced therapies.
Founded: 2013 | Headquarters: Frederick, Maryland, USA
Why It Ranks:
RoosterBio has been known for manufacturing technologies to aid in the production of exosomes and cell therapies on a commercial scale.
Regional Dominance:
North America, Europe, and Asia-Pacific regions.
Product Line:
Exosome manufacturing technology, mesenchymal stem cells, cell culture media, bioprocess solutions, and regenerative medicine products.
Recent Development:
In 2025, RoosterBio introduced scalable exosome manufacturing technology for clinical and commercial applications.
10. Codiak BioSciences, Inc.
Codiak BioSciences, Inc. is a biotechnology company that is based in the city of Cambridge. Codiak BioSciences specializes in developing exosomes as precision therapeutics for oncology and rare diseases.
Founded: 2015 | Headquarters: Cambridge, Massachusetts, USA
Why It Ranks:
Codiak BioSciences is known for developing engineered exosome therapeutics and targeted extracellular vesicles technologies.
Regional Dominance:
North America along with global research partnerships.
Product Line:
Engineered exosome therapeutics, targeted drug delivery technology, oncology treatments, and extracellular vesicle technology.
Recent Development:
In 2025, the company made further progress in developing its engineered exosome platform through research and therapeutic programs.
Schedule a meeting with our market experts to discuss the exclusive Exosomes Market report and identify the best research solution for your organization.
Conclusion
The Exosomes Market stands on the cusp of great expansion with increasing innovations in the field of exosome technology that have been used for the purpose of improving drug delivery, regenerative medicine, diagnostics and precision healthcare. The increased research on extracellular vesicles, clinical trials and development of exosome isolation, characterization and manufacturing are contributing to the expansion of the market of therapeutic and diagnostic solutions based on exosomes. The increased incidence of cancer, neurological disease, heart diseases and other chronic illnesses is also contributing to the demand for innovative applications of exosomes. Prominent players such as Thermo Fisher Scientific Inc., Lonza Group AG, Bio-Techne Corporation, QIAGEN N.V., SBI (System Biosciences LLC), Aegle Therapeutics Corporation, Capricor Therapeutics, Inc., Evox Therapeutics Ltd., RoosterBio, Inc., and Codiak BioSciences, Inc. are contributing to the growth of the market with their innovations and collaborations in research and manufacturing.
Send us a brief description of your challenge and we'll get back to you within 24 hours.
inquiry@transpireinsight.com
APAC:+91 7666513636
Address
